Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nigel H Russell

Showing results (71-80 of 112) with videos related to

Pageof 12
Sort By:
Hemasphere|August 27, 2025
A pooled analysis of 3 large multicenter trials confirms a survival advantage for <i>NPM1</i> <sup>mut</sup> AML in MRD<sup>neg</sup> remission after intensive inductionKonstanze Döhner, Hartmut Döhner, Daniela Späth, et al.
British Journal of Haematology|May 28, 2020
Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low-intensity chemotherapy in acute myeloid leukaemiaIng S Tiong, Richard Dillon, Adam Ivey, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 12, 2024
Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With <i>NPM1</i> and <i>FLT3</i> MutationsNigel H Russell, Charlotte Wilhelm-Benartzi, Jad Othman, et al.
Blood|February 16, 2024
Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remissionJad Othman, Nicola Potter, Adam Ivey, et al.
Oncology and Therapy|June 13, 2022
Patient, Family Member and Physician Perspectives and Experiences with AML Treatment Decision-MakingThomas W LeBlanc, Nigel H Russell, Loriana Hernandez-Aldama, et al.
Blood|October 25, 2011
The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysisGareth J Morgan, Walter M Gregory, Faith E Davies, et al.
Haematologica|November 8, 2011
Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial resultsGareth J Morgan, Faith E Davies, Walter M Gregory, et al.
Blood|September 24, 2024
Pretransplant MRD detection of fusion transcripts is strongly prognostic in KMT2A-rearranged acute myeloid leukemiaSun Loo, Nicola Potter, Adam Ivey, et al.
Blood|June 10, 2011
Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantationGareth J Morgan, Faith E Davies, Walter M Gregory, et al.
Blood|August 12, 2022
Pretransplant FLT3-ITD MRD assessed by high-sensitivity PCR-NGS determines posttransplant clinical outcomeSun Loo, Richard Dillon, Adam Ivey, et al.
Pageof 12

Showing results (71-80 of 112) with videos related to

Sort By:
Pageof 12
Hemasphere|August 27, 2025
A pooled analysis of 3 large multicenter trials confirms a survival advantage for <i>NPM1</i> <sup>mut</sup> AML in MRD<sup>neg</sup> remission after intensive inductionKonstanze Döhner, Hartmut Döhner, Daniela Späth, et al.
British Journal of Haematology|May 28, 2020
Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low-intensity chemotherapy in acute myeloid leukaemiaIng S Tiong, Richard Dillon, Adam Ivey, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 12, 2024
Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With <i>NPM1</i> and <i>FLT3</i> MutationsNigel H Russell, Charlotte Wilhelm-Benartzi, Jad Othman, et al.
Blood|February 16, 2024
Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remissionJad Othman, Nicola Potter, Adam Ivey, et al.
Oncology and Therapy|June 13, 2022
Patient, Family Member and Physician Perspectives and Experiences with AML Treatment Decision-MakingThomas W LeBlanc, Nigel H Russell, Loriana Hernandez-Aldama, et al.
Blood|October 25, 2011
The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysisGareth J Morgan, Walter M Gregory, Faith E Davies, et al.
Haematologica|November 8, 2011
Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial resultsGareth J Morgan, Faith E Davies, Walter M Gregory, et al.
Blood|September 24, 2024
Pretransplant MRD detection of fusion transcripts is strongly prognostic in KMT2A-rearranged acute myeloid leukemiaSun Loo, Nicola Potter, Adam Ivey, et al.
Blood|June 10, 2011
Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantationGareth J Morgan, Faith E Davies, Walter M Gregory, et al.
Blood|August 12, 2022
Pretransplant FLT3-ITD MRD assessed by high-sensitivity PCR-NGS determines posttransplant clinical outcomeSun Loo, Richard Dillon, Adam Ivey, et al.
Pageof 12